SALL2 and breast cancer: As shown in Figs 1E and EV1C–F, silencing SALL2 significantly decreased ESR1 transcription levels and abolished tamoxifen‐induced growth inhibition in ER+ breast cancer cells, including MCF7, T47D, and ZR‐75‐1.